Are you Dr. Archdeacon?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 63 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
101 Manning Dr
Chapel Hill, NC 27514Phone+1 919-966-4996Fax+1 919-843-5515
Summary
- Dr. Patrick Archdeacon, MD is a nephrologist in Chapel Hill, North Carolina. He is currently licensed to practice medicine in North Carolina and Maryland.
Education & Training
- University of North Carolina HospitalsFellowship, Nephrology, 2005 - 2007
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
- Columbia University Vagelos College of Physicians and SurgeonsClass of 2001
Certifications & Licensure
- MD State Medical License 2017 - 2024
- NC State Medical License 2006 - 2019
- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 12 citationsFDA-Catalyst—Using FDA’s Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial:Noelle M. Cocoros, Sean D. Pokorney, Kevin Haynes, Crystal Garcia, Hussein R. Al-Khalidi
Clinical Trials. 2019-02-01 - 5 citationsEvaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug-outcome associations: The case of clindamycin and Clos...Ryan M. Carnahan, Jennifer L. Kuntz, Shirley V. Wang, Candace C. Fuller, Joshua J. Gagne
Pharmacoepidemiology and Drug Safety. 2018-07-01 - 40 citationsRecommendations for data monitoring committees from the Clinical Trials Transformation Initiative.Karim A. Calis, Patrick Archdeacon, Raymond P. Bain, David L. DeMets, Miriam Donohue
Clinical Trials. 2017-05-13
Press Mentions
- New Drug Watch: A Validation of the ‘Twincretin’ Approach to Type 2 DiabetesJune 24th, 2022
- FDA Approves Novel, Dual-Targeted Treatment for Type 2 DiabetesMay 13th, 2022
- FDA Approves New Lilly Diabetes TreatmentMay 13th, 2022
- Join now to see all